Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

BACE1: Target For A Potential Alzheimer’s Disease Cure

Alzheimer’s disease (AD) is one of the most common forms of dementia that causes memory and behavioral problems. It is a progressive disease with most cases starting in people over 65 years old. Initially, the symptoms are often attributed to ageing or stress. During the advanced stages, patients are completely dependent on caregivers, making AD one of the most costly diseases to manage. Currently, there are no treatments to stop or reverse disease progression. However, some treatments can improve the quality of life and slow the worsening dementia symptoms. There are many hypotheses for the cause of Alzheimer’s including genetics, amyloid plaques and tau protein abnormalities. Presently, there are no effective measures in preventing AD, although a healthy diet and lifestyle may reduce the risk of developing Alzheimer’s.

A recent report examined the effects of a drug called Verubecestat in AD human and animal trials. The drug targets the production of protein plaques that are associated with AD. The drug functions as a BACE1 (beta-site amyloid precursor protein cleaving enzyme 1) inhibitor involved in producing a protein called amyloid beta that forms the plaques. Amyloid is formed when amyloid precursor protein (APP) is cleaved by BACE1 and gamma-secretase. Plaque buildup in the brain may lead to neurodegeneration therefore, by blocking BACE1, the build-up of amyloid beta could be avoided to slow down or prevent AD development. The BACE1 inhibitor is now progressing to phase 3 clinical trials involving 1,500 patients before it can be given to AD patients. Promisingly, no major side effects have been identified.

For more information:

Enzo Life Sciences provides a wide variety of products for your Neuroscience research needs. We offer a range of Neurodegenerative markers for ALS, Spinal Muscular Atrophy, Alzheimer’s, Parkinson’s, and Huntington’s disease. Our product portfolio fuels discovery in the etiology, pathology and treatment of neurodegenerative disease including our BACE1 (human), (recombinant) protein.

Never miss a new TechNote!

Receive our TechNotes as soon as they are published.

comments powered by Disqus

follow Us!


Related Products

BACE2 (soluble) (human), (recombinant) (His-tag) 

Highly active
Produced in insect cells. Recombinant soluble BACE2, cloned from human cDNA, secreted as zymogen from insect cells, purified using a C-terminal His-tag, and cleaved to the mature active form. Produced in a baculovirus expression system., ≥80% (SDS-PAGE) | Print as PDF
BML-SE550-0010 10 µg 482.00 USD
Do you need bulk/larger quantities?


Protease substrate
Synthetic., ≥98% (HPLC) | Print as PDF
BML-P227-0001 1 mg 206.00 USD
Do you need bulk/larger quantities?

Cathepsin D (human liver), (purified) 

Isolated from human liver., ≥95% (SDS-PAGE) | Print as PDF
BML-SE199-0025 25 µg 286.00 USD
Do you need bulk/larger quantities?

Cathepsin D & E substrate (fluorogenic) 

Synthetic substrate useful for inhibitor screening and kinetic analysis
Synthetic, ≥95% (HPLC) | Print as PDF
BML-P145-0001 1 mg 206.00 USD
Do you need bulk/larger quantities?

Recommend this page